Emergent Biosolutions (NYSE:EBS) EVP Coleen Glessner Sells 30,608 Shares

Key Points

• Coleen Glessner, the executive vice president of Emergent Biosolutions, sold 30,608 shares for $306,080, representing a 17.50% decrease in her holdings.
• Emergent Biosolutions' stock price declined by 2.3% to $9.38, with a trading volume of 958,055 shares on Thursday.
• The company has a market capitalization of $500.42 million and reported a negative EPS of ($1.27) for its most recent quarter.

Emergent Biosolutions Inc. (NYSE:EBS - Get Free Report) EVP Coleen Glessner sold 30,608 shares of the stock in a transaction on Tuesday, October 7th. The stock was sold at an average price of $10.00, for a total value of $306,080.00. Following the transaction, the executive vice president directly owned 144,319 shares in the company, valued at $1,443,190. The trade was a 17.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Emergent Biosolutions Stock Down 2.3%

Shares of NYSE:EBS traded down $0.22 during trading hours on Thursday, hitting $9.38. The company's stock had a trading volume of 958,055 shares, compared to its average volume of 1,195,734. The firm's fifty day moving average price is $8.65 and its 200 day moving average price is $6.91. Emergent Biosolutions Inc. has a 52 week low of $4.02 and a 52 week high of $12.73. The company has a market capitalization of $500.42 million, a price-to-earnings ratio of 3.83 and a beta of 2.04. The company has a debt-to-equity ratio of 1.25, a current ratio of 5.66 and a quick ratio of 3.00.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last issued its quarterly earnings data on Tuesday, January 9th. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter. The business had revenue of $222.50 million for the quarter. Emergent Biosolutions had a net margin of 16.38% and a return on equity of 24.63%. Emergent Biosolutions has set its FY 2023 guidance at EPS. As a group, research analysts expect that Emergent Biosolutions Inc. will post -0.63 EPS for the current year.

Institutional Investors Weigh In On Emergent Biosolutions

A number of institutional investors and hedge funds have recently modified their holdings of the company. Legal & General Group Plc acquired a new position in Emergent Biosolutions in the 2nd quarter worth approximately $31,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Emergent Biosolutions in the second quarter worth $35,000. Raymond James Financial Inc. acquired a new stake in shares of Emergent Biosolutions in the second quarter worth $53,000. Janney Montgomery Scott LLC purchased a new position in shares of Emergent Biosolutions during the second quarter worth $68,000. Finally, ProShare Advisors LLC acquired a new position in Emergent Biosolutions during the second quarter valued at $71,000. Institutional investors and hedge funds own 78.40% of the company's stock.

Analyst Upgrades and Downgrades

EBS has been the topic of several analyst reports. HC Wainwright reiterated a "buy" rating and issued a $15.00 target price on shares of Emergent Biosolutions in a research note on Wednesday, September 3rd. Wall Street Zen lowered Emergent Biosolutions from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Finally, Weiss Ratings restated a "sell (d)" rating on shares of Emergent Biosolutions in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $13.50.

About Emergent Biosolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.